# The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

Study · id `cardio:ct-nct05386186` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05386186](<https://clinicaltrials.gov/study/NCT05386186>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05386186

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 192 participants.

## Technical summary

Registry record NCT05386186. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2023-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 192 participants (planned count; ClinicalTrials.gov record NCT05386186, source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT05386186, source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)
- Primary completion: 2023-10-31 (anticipated) (ClinicalTrials.gov record NCT05386186, source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)
- Completion: 2024-03-31 (anticipated) (ClinicalTrials.gov record NCT05386186, source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05386186, source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05386186-2022-05-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes
- Condition: Diabetes Mellitus, Type 2
- Condition: Severe Insulin Deficient Diabetes
- Intervention (Drug): Glimepiride
- Intervention (Drug): Sitagliptin
- Lead sponsor: Peking University People's Hospital
- Lead sponsor class: OTHER
- Collaborator: Peking University First Hospital
- Collaborator class: OTHER
- Collaborator: Jiangsu Province Geriatric Institute
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Peking University People's Hospital (`cardio:org-peking-university-people-s-hospital`)
- Registry lists this organization as a collaborator: Peking University First Hospital (`cardio:org-peking-university-first-hospital`)

## Provenance

Content hash: c6ba827bb3ab0470ebb54d1b6c39d2bc2cc1f4deff0555eba3996eb921e99240
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
